Question 1

What is the catalog number for CD62L (Biotin) discontinued?

Accepted Answer

The catalog number for CD62L (Biotin) discontinued is 516449.

Question 2

What sizes are available for CD62L (Biotin) discontinued?

Accepted Answer

CD62L (Biotin) discontinued is available in the following size(s): 25 µg, 100 µg.

Question 3

How many pack sizes does CD62L (Biotin) discontinued come in?

Accepted Answer

CD62L (Biotin) discontinued is available in 2 different pack sizes.

Question 4

Is CD62L (Biotin) discontinued in stock?

Accepted Answer

CD62L (Biotin) discontinued is currently made to order / not held in immediate stock. Contact us for lead time.

Question 5

What is the isotype of this antibody?

Accepted Answer

Isotype information such as IgG1 or IgG2a is listed in the product specifications on the datasheet, relevant for selecting compatible detection reagents.

Question 6

Can I get a trial-size or discounted first order of this product?

Accepted Answer

We don’t generally offer free samples, but trial discounts in exchange for feedback and validation results are almost always possible. Contact us with your intended application to arrange one.

Question 7

Do you offer bulk or custom quantities of this product?

Accepted Answer

Yes. Ordering two or more units, or combining this with other products, usually qualifies for a discount depending on quantity. Contact our sales team with your required volume for a custom quote.

CD62L (Biotin) discontinued

Product Specifications

Clonality

Available Sizes

Frequently Asked Questions

Explore Other Products

PPP2R2B (Protein Phosphatase 2 (formerly 2A), Regulatory Subunit B, beta isoform, B55-BETA, FLJ95686, MGC24888, PP2A-B55BETA, PP2A-PR55B, PP2AB-BETA, PP2APR55-BETA, PR2AB-BETA, PR2AB55-BETA, PR2APR55-BETA, PR52B, PR55-BETA, SCA12) (HRP)

Lentiviral human CHIC1 shRNA (UAS) - Lentiviral human CHIC1 shRNA (UAS) (25)

Sodium cholate hydrate

NTRK1 CRISPRa sgRNA lentivector (set of three targets)(Mouse)

MTTFX sgRNA CRISPR Lentivector (Human) (Target 3)

Palivizumab